Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range

Punam Sandhu, John S. Vogel, Mark J. Rose, Esther A. Ubick, Janice E. Brunner, Michael A. Wallace, Jennifer K. Adelsberger, Maribeth P. Baker, Paul Henderson, Paul G. Pearson, Thomas A. Baillie

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The technique of accelerator mass spectrometry (AMS) was validated successfully and used to study the pharmacokinetics and disposition in dogs of a preclinical drug candidate (7-deaza-2′-C-methyl-adenosine; Compound A), after oral and intravenous administration. The primary objective of this study was to examine whether Compound A displayed linear kinetics across subpharmacological (microdose) and pharmacological dose ranges in an animal model, before initiation of a human microdose study. The AMS-derived disposition properties of Compound A were comparable to data obtained via conventional techniques such as liquid chromatography-tandem mass spectrometry and liquid scintillation counting analyses. Compound A displayed multiphasic kinetics and exhibited low plasma clearance (5.8 ml/min/kg), a long terminal elimination half-life (17.5 h), and high oral bioavailability (103%). Currently, there are no published comparisons of the kinetics of a pharmaceutical compound at pharmacological versus subpharmacological doses using microdosing strategies. The present study thus provides the first description of the full pharmacokinetic profile of a drug candidate assessed under these two dosing regimens. The data demonstrated that the pharmacokinetic properties of Compound A following dosing at 0.02 mg/kg were similar to those at 1 mg/kg, indicating that in the case of Compound A, the pharmacokinetics in the dog appear to be linear across this 50-fold dose range. Moreover, the exceptional sensitivity of AMS provided a pharmacokinetic profile of Compound A, even after a microdose, which revealed aspects of the disposition of this agent that were inaccessible by conventional techniques.

Original languageEnglish (US)
Pages (from-to)1254-1259
Number of pages6
JournalDrug Metabolism and Disposition
Volume32
Issue number11
DOIs
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

Pharmacokinetics
Nucleosides
Demonstrations
Mass spectrometry
Dogs
Particle accelerators
Mass Spectrometry
Pharmaceutical Preparations
Kinetics
Pharmacology
Scintillation Counting
Liquid chromatography
Scintillation
Tandem Mass Spectrometry
Liquid Chromatography
Intravenous Administration
Adenosine
Biological Availability
Oral Administration
Half-Life

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Evaluation of microdosing strategies for studies in preclinical drug development : Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. / Sandhu, Punam; Vogel, John S.; Rose, Mark J.; Ubick, Esther A.; Brunner, Janice E.; Wallace, Michael A.; Adelsberger, Jennifer K.; Baker, Maribeth P.; Henderson, Paul; Pearson, Paul G.; Baillie, Thomas A.

In: Drug Metabolism and Disposition, Vol. 32, No. 11, 11.2004, p. 1254-1259.

Research output: Contribution to journalArticle

Sandhu, Punam ; Vogel, John S. ; Rose, Mark J. ; Ubick, Esther A. ; Brunner, Janice E. ; Wallace, Michael A. ; Adelsberger, Jennifer K. ; Baker, Maribeth P. ; Henderson, Paul ; Pearson, Paul G. ; Baillie, Thomas A. / Evaluation of microdosing strategies for studies in preclinical drug development : Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. In: Drug Metabolism and Disposition. 2004 ; Vol. 32, No. 11. pp. 1254-1259.
@article{a5b6a21273de4b66bb0c9afa1b4c0225,
title = "Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range",
abstract = "The technique of accelerator mass spectrometry (AMS) was validated successfully and used to study the pharmacokinetics and disposition in dogs of a preclinical drug candidate (7-deaza-2′-C-methyl-adenosine; Compound A), after oral and intravenous administration. The primary objective of this study was to examine whether Compound A displayed linear kinetics across subpharmacological (microdose) and pharmacological dose ranges in an animal model, before initiation of a human microdose study. The AMS-derived disposition properties of Compound A were comparable to data obtained via conventional techniques such as liquid chromatography-tandem mass spectrometry and liquid scintillation counting analyses. Compound A displayed multiphasic kinetics and exhibited low plasma clearance (5.8 ml/min/kg), a long terminal elimination half-life (17.5 h), and high oral bioavailability (103{\%}). Currently, there are no published comparisons of the kinetics of a pharmaceutical compound at pharmacological versus subpharmacological doses using microdosing strategies. The present study thus provides the first description of the full pharmacokinetic profile of a drug candidate assessed under these two dosing regimens. The data demonstrated that the pharmacokinetic properties of Compound A following dosing at 0.02 mg/kg were similar to those at 1 mg/kg, indicating that in the case of Compound A, the pharmacokinetics in the dog appear to be linear across this 50-fold dose range. Moreover, the exceptional sensitivity of AMS provided a pharmacokinetic profile of Compound A, even after a microdose, which revealed aspects of the disposition of this agent that were inaccessible by conventional techniques.",
author = "Punam Sandhu and Vogel, {John S.} and Rose, {Mark J.} and Ubick, {Esther A.} and Brunner, {Janice E.} and Wallace, {Michael A.} and Adelsberger, {Jennifer K.} and Baker, {Maribeth P.} and Paul Henderson and Pearson, {Paul G.} and Baillie, {Thomas A.}",
year = "2004",
month = "11",
doi = "10.1124/dmd.104.000422",
language = "English (US)",
volume = "32",
pages = "1254--1259",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "11",

}

TY - JOUR

T1 - Evaluation of microdosing strategies for studies in preclinical drug development

T2 - Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range

AU - Sandhu, Punam

AU - Vogel, John S.

AU - Rose, Mark J.

AU - Ubick, Esther A.

AU - Brunner, Janice E.

AU - Wallace, Michael A.

AU - Adelsberger, Jennifer K.

AU - Baker, Maribeth P.

AU - Henderson, Paul

AU - Pearson, Paul G.

AU - Baillie, Thomas A.

PY - 2004/11

Y1 - 2004/11

N2 - The technique of accelerator mass spectrometry (AMS) was validated successfully and used to study the pharmacokinetics and disposition in dogs of a preclinical drug candidate (7-deaza-2′-C-methyl-adenosine; Compound A), after oral and intravenous administration. The primary objective of this study was to examine whether Compound A displayed linear kinetics across subpharmacological (microdose) and pharmacological dose ranges in an animal model, before initiation of a human microdose study. The AMS-derived disposition properties of Compound A were comparable to data obtained via conventional techniques such as liquid chromatography-tandem mass spectrometry and liquid scintillation counting analyses. Compound A displayed multiphasic kinetics and exhibited low plasma clearance (5.8 ml/min/kg), a long terminal elimination half-life (17.5 h), and high oral bioavailability (103%). Currently, there are no published comparisons of the kinetics of a pharmaceutical compound at pharmacological versus subpharmacological doses using microdosing strategies. The present study thus provides the first description of the full pharmacokinetic profile of a drug candidate assessed under these two dosing regimens. The data demonstrated that the pharmacokinetic properties of Compound A following dosing at 0.02 mg/kg were similar to those at 1 mg/kg, indicating that in the case of Compound A, the pharmacokinetics in the dog appear to be linear across this 50-fold dose range. Moreover, the exceptional sensitivity of AMS provided a pharmacokinetic profile of Compound A, even after a microdose, which revealed aspects of the disposition of this agent that were inaccessible by conventional techniques.

AB - The technique of accelerator mass spectrometry (AMS) was validated successfully and used to study the pharmacokinetics and disposition in dogs of a preclinical drug candidate (7-deaza-2′-C-methyl-adenosine; Compound A), after oral and intravenous administration. The primary objective of this study was to examine whether Compound A displayed linear kinetics across subpharmacological (microdose) and pharmacological dose ranges in an animal model, before initiation of a human microdose study. The AMS-derived disposition properties of Compound A were comparable to data obtained via conventional techniques such as liquid chromatography-tandem mass spectrometry and liquid scintillation counting analyses. Compound A displayed multiphasic kinetics and exhibited low plasma clearance (5.8 ml/min/kg), a long terminal elimination half-life (17.5 h), and high oral bioavailability (103%). Currently, there are no published comparisons of the kinetics of a pharmaceutical compound at pharmacological versus subpharmacological doses using microdosing strategies. The present study thus provides the first description of the full pharmacokinetic profile of a drug candidate assessed under these two dosing regimens. The data demonstrated that the pharmacokinetic properties of Compound A following dosing at 0.02 mg/kg were similar to those at 1 mg/kg, indicating that in the case of Compound A, the pharmacokinetics in the dog appear to be linear across this 50-fold dose range. Moreover, the exceptional sensitivity of AMS provided a pharmacokinetic profile of Compound A, even after a microdose, which revealed aspects of the disposition of this agent that were inaccessible by conventional techniques.

UR - http://www.scopus.com/inward/record.url?scp=6944241355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6944241355&partnerID=8YFLogxK

U2 - 10.1124/dmd.104.000422

DO - 10.1124/dmd.104.000422

M3 - Article

C2 - 15286054

AN - SCOPUS:6944241355

VL - 32

SP - 1254

EP - 1259

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 11

ER -